News - solanezumab, Research


Current filters:


Popular Filters

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development


In yet another research disappointment, US drug major Bristol-Myers Squibb (NYSE: BMY) recently assessed…

avagacestatbapineuzumabBristol-Myers SquibbMK-8931NeurologicalPharmaceuticalResearchsolanezumab

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial


Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased


US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld


US drug major Eli Lilly (NYSE: LLY) revealed last Friday that the primary endpoints, both cognitive and…

AlimtaEli LillyLegalNeurologicalNorth AmericaOncologyPatentsPharmaceuticalResearchsolanezumabTeva Pharmaceutical Industries

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top